PIA
FPRX

Piedmont Investment Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Piedmont Investment Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-576
Closed -$9K – 2668
2018
Q2 		$9K Buy
+576
New +$10.1K ﹤0.01% 1895

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Piedmont Investment Advisors's FPRX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 576 shares — an estimated $9K sold.

Piedmont Investment Advisors first reported a position in FPRX in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 576 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $9K.
  • Piedmont Investment Advisors first reported a position in Five Prime Therapeutics, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Five Prime Therapeutics, Inc. position peaked at $9K in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.